nodes	percent_of_prediction	percent_of_DWPC	metapath
Finasteride—Medrysone—Methylprednisolone—multiple sclerosis	0.19	0.322	CrCrCtD
Finasteride—Medrysone—Prednisolone—multiple sclerosis	0.169	0.286	CrCrCtD
Finasteride—Progesterone—Prednisolone—multiple sclerosis	0.124	0.21	CrCrCtD
Finasteride—Testosterone—Prednisolone—multiple sclerosis	0.108	0.182	CrCrCtD
Finasteride—CYP3A4—Fingolimod—multiple sclerosis	0.0408	0.157	CbGbCtD
Finasteride—CYP3A7—Dexamethasone—multiple sclerosis	0.034	0.131	CbGbCtD
Finasteride—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.034	0.131	CbGbCtD
Finasteride—CYP3A4—Methylprednisolone—multiple sclerosis	0.0263	0.101	CbGbCtD
Finasteride—CYP3A5—Dexamethasone—multiple sclerosis	0.0255	0.0982	CbGbCtD
Finasteride—CYP3A4—Triamcinolone—multiple sclerosis	0.0199	0.0768	CbGbCtD
Finasteride—CYP3A4—Mitoxantrone—multiple sclerosis	0.0192	0.0739	CbGbCtD
Finasteride—CYP3A4—Betamethasone—multiple sclerosis	0.0171	0.0659	CbGbCtD
Finasteride—CYP3A4—Prednisolone—multiple sclerosis	0.0169	0.065	CbGbCtD
Finasteride—CYP3A4—Prednisone—multiple sclerosis	0.0159	0.0614	CbGbCtD
Finasteride—CYP3A4—Dexamethasone—multiple sclerosis	0.00996	0.0383	CbGbCtD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—CYP24A1—multiple sclerosis	0.00749	0.0974	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—CYP27B1—multiple sclerosis	0.00749	0.0974	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—CYP24A1—multiple sclerosis	0.00749	0.0974	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—CYP27B1—multiple sclerosis	0.00749	0.0974	CbGpPWpGaD
Finasteride—SRD5A2—Androgen biosynthesis—POMC—multiple sclerosis	0.00406	0.0528	CbGpPWpGaD
Finasteride—SRD5A1—Androgen biosynthesis—POMC—multiple sclerosis	0.00406	0.0528	CbGpPWpGaD
Finasteride—Dydrogesterone—PGR—multiple sclerosis	0.00329	0.796	CrCbGaD
Finasteride—Neoplasm malignant—Cladribine—multiple sclerosis	0.00178	0.0261	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.00176	0.0229	CbGpPWpGaD
Finasteride—AKR1D1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.00176	0.0229	CbGpPWpGaD
Finasteride—Trauma—Prednisolone—multiple sclerosis	0.00172	0.0252	CcSEcCtD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—POMC—multiple sclerosis	0.00168	0.0219	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—POMC—multiple sclerosis	0.00168	0.0219	CbGpPWpGaD
Finasteride—Influenza—Fingolimod—multiple sclerosis	0.00168	0.0246	CcSEcCtD
Finasteride—Bronchitis—Fingolimod—multiple sclerosis	0.00162	0.0237	CcSEcCtD
Finasteride—Trauma—Triamcinolone—multiple sclerosis	0.00158	0.0232	CcSEcCtD
Finasteride—Trauma—Methylprednisolone—multiple sclerosis	0.00158	0.0231	CcSEcCtD
Finasteride—Neoplasm malignant—Azathioprine—multiple sclerosis	0.00145	0.0212	CcSEcCtD
Finasteride—Trauma—Dexamethasone—multiple sclerosis	0.00144	0.021	CcSEcCtD
Finasteride—Trauma—Betamethasone—multiple sclerosis	0.00144	0.021	CcSEcCtD
Finasteride—Sinusitis—Fingolimod—multiple sclerosis	0.00141	0.0206	CcSEcCtD
Finasteride—Neoplasm—Cladribine—multiple sclerosis	0.00137	0.0201	CcSEcCtD
Finasteride—AKR1D1—Bile acid and bile salt metabolism—ALB—multiple sclerosis	0.00128	0.0166	CbGpPWpGaD
Finasteride—Trauma—Prednisone—multiple sclerosis	0.00125	0.0183	CcSEcCtD
Finasteride—Swelling—Cladribine—multiple sclerosis	0.00125	0.0183	CcSEcCtD
Finasteride—Mental disorder—Fingolimod—multiple sclerosis	0.00118	0.0173	CcSEcCtD
Finasteride—Neoplasm—Azathioprine—multiple sclerosis	0.00112	0.0164	CcSEcCtD
Finasteride—Infection—Fingolimod—multiple sclerosis	0.00095	0.0139	CcSEcCtD
Finasteride—Hypotension—Fingolimod—multiple sclerosis	0.000893	0.0131	CcSEcCtD
Finasteride—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.000882	0.0115	CbGpPWpGaD
Finasteride—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000875	0.0114	CbGpPWpGaD
Finasteride—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000875	0.0114	CbGpPWpGaD
Finasteride—CYP3A7—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000864	0.0112	CbGpPWpGaD
Finasteride—CYP3A7—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000864	0.0112	CbGpPWpGaD
Finasteride—Dyspnoea—Fingolimod—multiple sclerosis	0.000852	0.0125	CcSEcCtD
Finasteride—Swelling—Mitoxantrone—multiple sclerosis	0.000821	0.012	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000768	0.00999	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000768	0.00999	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000768	0.00999	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000768	0.00999	CbGpPWpGaD
Finasteride—Pharyngitis—Cladribine—multiple sclerosis	0.000757	0.0111	CcSEcCtD
Finasteride—Oedema peripheral—Cladribine—multiple sclerosis	0.000751	0.011	CcSEcCtD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.00071	0.00923	CbGpPWpGaD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.00071	0.00923	CbGpPWpGaD
Finasteride—Immune system disorder—Cladribine—multiple sclerosis	0.000689	0.0101	CcSEcCtD
Finasteride—Asthenia—Fingolimod—multiple sclerosis	0.000686	0.0101	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	0.000684	0.0089	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	0.000684	0.0089	CbGpPWpGaD
Finasteride—Pruritus—Fingolimod—multiple sclerosis	0.000676	0.00991	CcSEcCtD
Finasteride—Mental disorder—Cladribine—multiple sclerosis	0.000668	0.00979	CcSEcCtD
Finasteride—Progesterone—PGR—multiple sclerosis	0.000666	0.161	CrCbGaD
Finasteride—Injury—Prednisolone—multiple sclerosis	0.000647	0.00948	CcSEcCtD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000633	0.00823	CbGpPWpGaD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000633	0.00823	CbGpPWpGaD
Finasteride—Dizziness—Fingolimod—multiple sclerosis	0.000632	0.00926	CcSEcCtD
Finasteride—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000625	0.00813	CbGpPWpGaD
Finasteride—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000625	0.00813	CbGpPWpGaD
Finasteride—Headache—Fingolimod—multiple sclerosis	0.000599	0.00878	CcSEcCtD
Finasteride—Injury—Triamcinolone—multiple sclerosis	0.000595	0.00872	CcSEcCtD
Finasteride—Injury—Methylprednisolone—multiple sclerosis	0.000593	0.0087	CcSEcCtD
Finasteride—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.000577	0.00845	CcSEcCtD
Finasteride—Immune system disorder—Azathioprine—multiple sclerosis	0.00056	0.00821	CcSEcCtD
Finasteride—Injury—Dexamethasone—multiple sclerosis	0.00054	0.00791	CcSEcCtD
Finasteride—Injury—Betamethasone—multiple sclerosis	0.00054	0.00791	CcSEcCtD
Finasteride—Infection—Cladribine—multiple sclerosis	0.000538	0.00789	CcSEcCtD
Finasteride—Sinusitis—Mitoxantrone—multiple sclerosis	0.000524	0.00768	CcSEcCtD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000513	0.00668	CbGpPWpGaD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000513	0.00668	CbGpPWpGaD
Finasteride—Hypotension—Cladribine—multiple sclerosis	0.000506	0.00742	CcSEcCtD
Finasteride—Rhinitis—Mitoxantrone—multiple sclerosis	0.000503	0.00737	CcSEcCtD
Finasteride—Pharyngitis—Mitoxantrone—multiple sclerosis	0.000498	0.00729	CcSEcCtD
Finasteride—Breast disorder—Methylprednisolone—multiple sclerosis	0.000493	0.00722	CcSEcCtD
Finasteride—SRD5A1—Metabolism—SRM—multiple sclerosis	0.000485	0.00631	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—SRM—multiple sclerosis	0.000485	0.00631	CbGpPWpGaD
Finasteride—Dyspnoea—Cladribine—multiple sclerosis	0.000483	0.00708	CcSEcCtD
Finasteride—Somnolence—Cladribine—multiple sclerosis	0.000482	0.00706	CcSEcCtD
Finasteride—Influenza—Triamcinolone—multiple sclerosis	0.000473	0.00693	CcSEcCtD
Finasteride—Injury—Prednisone—multiple sclerosis	0.00047	0.00689	CcSEcCtD
Finasteride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000463	0.00603	CbGpPWpGaD
Finasteride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000463	0.00603	CbGpPWpGaD
Finasteride—Pain—Cladribine—multiple sclerosis	0.000463	0.00679	CcSEcCtD
Finasteride—Bronchitis—Triamcinolone—multiple sclerosis	0.000454	0.00666	CcSEcCtD
Finasteride—Neoplasm—Methotrexate—multiple sclerosis	0.00045	0.00659	CcSEcCtD
Finasteride—Gynaecomastia—Methotrexate—multiple sclerosis	0.000445	0.00652	CcSEcCtD
Finasteride—Infection—Azathioprine—multiple sclerosis	0.000438	0.00641	CcSEcCtD
Finasteride—AKR1D1—Metabolism—SRM—multiple sclerosis	0.000432	0.00563	CbGpPWpGaD
Finasteride—Urticaria—Cladribine—multiple sclerosis	0.00043	0.00631	CcSEcCtD
Finasteride—Hypotension—Azathioprine—multiple sclerosis	0.000412	0.00603	CcSEcCtD
Finasteride—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.00041	0.00534	CbGpPWpGaD
Finasteride—Hypersensitivity—Cladribine—multiple sclerosis	0.000399	0.00585	CcSEcCtD
Finasteride—Asthenia—Cladribine—multiple sclerosis	0.000389	0.0057	CcSEcCtD
Finasteride—Pruritus—Cladribine—multiple sclerosis	0.000383	0.00562	CcSEcCtD
Finasteride—Rhinitis—Triamcinolone—multiple sclerosis	0.000379	0.00556	CcSEcCtD
Finasteride—Rhinitis—Methylprednisolone—multiple sclerosis	0.000378	0.00554	CcSEcCtD
Finasteride—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.000377	0.00491	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.000377	0.00491	CbGpPWpGaD
Finasteride—Pharyngitis—Triamcinolone—multiple sclerosis	0.000375	0.0055	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000372	0.00484	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000372	0.00484	CbGpPWpGaD
Finasteride—Dizziness—Cladribine—multiple sclerosis	0.000358	0.00525	CcSEcCtD
Finasteride—Infection—Mitoxantrone—multiple sclerosis	0.000354	0.00519	CcSEcCtD
Finasteride—Erectile dysfunction—Prednisone—multiple sclerosis	0.000344	0.00504	CcSEcCtD
Finasteride—SRD5A2—Metabolism—CYP27B1—multiple sclerosis	0.000342	0.00445	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—CYP24A1—multiple sclerosis	0.000342	0.00445	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—CYP27B1—multiple sclerosis	0.000342	0.00445	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—CYP24A1—multiple sclerosis	0.000342	0.00445	CbGpPWpGaD
Finasteride—Rash—Cladribine—multiple sclerosis	0.000342	0.00501	CcSEcCtD
Finasteride—Dermatitis—Cladribine—multiple sclerosis	0.000341	0.005	CcSEcCtD
Finasteride—Immune system disorder—Methylprednisolone—multiple sclerosis	0.000341	0.005	CcSEcCtD
Finasteride—Headache—Cladribine—multiple sclerosis	0.000339	0.00497	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000334	0.00435	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000334	0.00435	CbGpPWpGaD
Finasteride—Hypotension—Mitoxantrone—multiple sclerosis	0.000333	0.00488	CcSEcCtD
Finasteride—Mental disorder—Methylprednisolone—multiple sclerosis	0.000331	0.00485	CcSEcCtD
Finasteride—Angioedema—Prednisolone—multiple sclerosis	0.000327	0.00479	CcSEcCtD
Finasteride—Breast disorder—Methotrexate—multiple sclerosis	0.000326	0.00478	CcSEcCtD
Finasteride—Hypersensitivity—Azathioprine—multiple sclerosis	0.000325	0.00476	CcSEcCtD
Finasteride—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000318	0.00465	CcSEcCtD
Finasteride—Somnolence—Mitoxantrone—multiple sclerosis	0.000317	0.00464	CcSEcCtD
Finasteride—SRD5A2—Metabolism—GPC5—multiple sclerosis	0.000313	0.00407	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—GPC5—multiple sclerosis	0.000313	0.00407	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—CYP24A1—multiple sclerosis	0.000305	0.00396	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—CYP27B1—multiple sclerosis	0.000305	0.00396	CbGpPWpGaD
Finasteride—Pain—Mitoxantrone—multiple sclerosis	0.000305	0.00446	CcSEcCtD
Finasteride—Angioedema—Triamcinolone—multiple sclerosis	0.000301	0.00441	CcSEcCtD
Finasteride—Angioedema—Methylprednisolone—multiple sclerosis	0.0003	0.0044	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	0.000298	0.00388	CbGpPWpGaD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000294	0.00383	CbGpPWpGaD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000294	0.00383	CbGpPWpGaD
Finasteride—Dizziness—Azathioprine—multiple sclerosis	0.000291	0.00427	CcSEcCtD
Finasteride—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00029	0.00378	CbGpPWpGaD
Finasteride—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00029	0.00378	CbGpPWpGaD
Finasteride—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000287	0.00421	CcSEcCtD
Finasteride—Urticaria—Mitoxantrone—multiple sclerosis	0.000283	0.00415	CcSEcCtD
Finasteride—AKR1D1—Metabolism—GPC5—multiple sclerosis	0.000279	0.00363	CbGpPWpGaD
Finasteride—Rash—Azathioprine—multiple sclerosis	0.000278	0.00407	CcSEcCtD
Finasteride—Dermatitis—Azathioprine—multiple sclerosis	0.000278	0.00407	CcSEcCtD
Finasteride—Headache—Azathioprine—multiple sclerosis	0.000276	0.00405	CcSEcCtD
Finasteride—Angioedema—Dexamethasone—multiple sclerosis	0.000273	0.004	CcSEcCtD
Finasteride—Angioedema—Betamethasone—multiple sclerosis	0.000273	0.004	CcSEcCtD
Finasteride—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000273	0.00355	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000273	0.00355	CbGpPWpGaD
Finasteride—Immune system disorder—Prednisone—multiple sclerosis	0.00027	0.00396	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000269	0.0035	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000269	0.0035	CbGpPWpGaD
Finasteride—Infection—Triamcinolone—multiple sclerosis	0.000267	0.00391	CcSEcCtD
Finasteride—Infection—Methylprednisolone—multiple sclerosis	0.000266	0.0039	CcSEcCtD
Finasteride—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000264	0.00343	CbGpPWpGaD
Finasteride—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000262	0.00385	CcSEcCtD
Finasteride—Mental disorder—Prednisone—multiple sclerosis	0.000262	0.00384	CcSEcCtD
Finasteride—SRD5A2—Metabolism—RRM1—multiple sclerosis	0.000259	0.00337	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—RRM1—multiple sclerosis	0.000259	0.00337	CbGpPWpGaD
Finasteride—Asthenia—Mitoxantrone—multiple sclerosis	0.000256	0.00375	CcSEcCtD
Finasteride—Hypotension—Methylprednisolone—multiple sclerosis	0.000251	0.00367	CcSEcCtD
Finasteride—Pain—Prednisolone—multiple sclerosis	0.00025	0.00366	CcSEcCtD
Finasteride—Pharyngitis—Methotrexate—multiple sclerosis	0.000248	0.00363	CcSEcCtD
Finasteride—Infection—Dexamethasone—multiple sclerosis	0.000242	0.00355	CcSEcCtD
Finasteride—Infection—Betamethasone—multiple sclerosis	0.000242	0.00355	CcSEcCtD
Finasteride—Dyspnoea—Triamcinolone—multiple sclerosis	0.00024	0.00351	CcSEcCtD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000239	0.0031	CbGpPWpGaD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000239	0.0031	CbGpPWpGaD
Finasteride—Angioedema—Prednisone—multiple sclerosis	0.000238	0.00348	CcSEcCtD
Finasteride—Urticaria—Prednisolone—multiple sclerosis	0.000232	0.0034	CcSEcCtD
Finasteride—AKR1D1—Metabolism—RRM1—multiple sclerosis	0.000231	0.003	CbGpPWpGaD
Finasteride—Pain—Triamcinolone—multiple sclerosis	0.00023	0.00337	CcSEcCtD
Finasteride—Hypotension—Dexamethasone—multiple sclerosis	0.000228	0.00334	CcSEcCtD
Finasteride—Hypotension—Betamethasone—multiple sclerosis	0.000228	0.00334	CcSEcCtD
Finasteride—Immune system disorder—Methotrexate—multiple sclerosis	0.000226	0.00331	CcSEcCtD
Finasteride—Rash—Mitoxantrone—multiple sclerosis	0.000225	0.00329	CcSEcCtD
Finasteride—Dermatitis—Mitoxantrone—multiple sclerosis	0.000224	0.00329	CcSEcCtD
Finasteride—Headache—Mitoxantrone—multiple sclerosis	0.000223	0.00327	CcSEcCtD
Finasteride—Mental disorder—Methotrexate—multiple sclerosis	0.000219	0.00321	CcSEcCtD
Finasteride—Hypersensitivity—Prednisolone—multiple sclerosis	0.000215	0.00316	CcSEcCtD
Finasteride—Urticaria—Triamcinolone—multiple sclerosis	0.000213	0.00313	CcSEcCtD
Finasteride—Urticaria—Methylprednisolone—multiple sclerosis	0.000213	0.00312	CcSEcCtD
Finasteride—Infection—Prednisone—multiple sclerosis	0.000211	0.00309	CcSEcCtD
Finasteride—Pain—Dexamethasone—multiple sclerosis	0.000209	0.00306	CcSEcCtD
Finasteride—Pain—Betamethasone—multiple sclerosis	0.000209	0.00306	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000201	0.00262	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000201	0.00262	CbGpPWpGaD
Finasteride—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000198	0.0029	CcSEcCtD
Finasteride—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000198	0.0029	CcSEcCtD
Finasteride—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000197	0.00256	CbGpPWpGaD
Finasteride—Urticaria—Dexamethasone—multiple sclerosis	0.000194	0.00284	CcSEcCtD
Finasteride—Urticaria—Betamethasone—multiple sclerosis	0.000194	0.00284	CcSEcCtD
Finasteride—Dizziness—Prednisolone—multiple sclerosis	0.000193	0.00283	CcSEcCtD
Finasteride—Asthenia—Triamcinolone—multiple sclerosis	0.000193	0.00283	CcSEcCtD
Finasteride—Asthenia—Methylprednisolone—multiple sclerosis	0.000192	0.00282	CcSEcCtD
Finasteride—Pruritus—Triamcinolone—multiple sclerosis	0.00019	0.00279	CcSEcCtD
Finasteride—Pruritus—Methylprednisolone—multiple sclerosis	0.00019	0.00278	CcSEcCtD
Finasteride—Rash—Prednisolone—multiple sclerosis	0.000184	0.0027	CcSEcCtD
Finasteride—Dermatitis—Prednisolone—multiple sclerosis	0.000184	0.0027	CcSEcCtD
Finasteride—Headache—Prednisolone—multiple sclerosis	0.000183	0.00268	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	0.000179	0.00233	CbGpPWpGaD
Finasteride—Dizziness—Triamcinolone—multiple sclerosis	0.000178	0.0026	CcSEcCtD
Finasteride—Dizziness—Methylprednisolone—multiple sclerosis	0.000177	0.0026	CcSEcCtD
Finasteride—Testosterone—ALB—multiple sclerosis	0.000177	0.0428	CrCbGaD
Finasteride—Infection—Methotrexate—multiple sclerosis	0.000176	0.00258	CcSEcCtD
Finasteride—Asthenia—Dexamethasone—multiple sclerosis	0.000175	0.00256	CcSEcCtD
Finasteride—Asthenia—Betamethasone—multiple sclerosis	0.000175	0.00256	CcSEcCtD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000173	0.00225	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000173	0.00225	CbGpPWpGaD
Finasteride—Pruritus—Betamethasone—multiple sclerosis	0.000173	0.00253	CcSEcCtD
Finasteride—Pruritus—Dexamethasone—multiple sclerosis	0.000173	0.00253	CcSEcCtD
Finasteride—Rash—Triamcinolone—multiple sclerosis	0.000169	0.00248	CcSEcCtD
Finasteride—Dermatitis—Triamcinolone—multiple sclerosis	0.000169	0.00248	CcSEcCtD
Finasteride—Rash—Methylprednisolone—multiple sclerosis	0.000169	0.00248	CcSEcCtD
Finasteride—Dermatitis—Methylprednisolone—multiple sclerosis	0.000169	0.00248	CcSEcCtD
Finasteride—Urticaria—Prednisone—multiple sclerosis	0.000169	0.00247	CcSEcCtD
Finasteride—Headache—Triamcinolone—multiple sclerosis	0.000168	0.00247	CcSEcCtD
Finasteride—Headache—Methylprednisolone—multiple sclerosis	0.000168	0.00246	CcSEcCtD
Finasteride—Hypotension—Methotrexate—multiple sclerosis	0.000166	0.00243	CcSEcCtD
Finasteride—Dizziness—Dexamethasone—multiple sclerosis	0.000161	0.00236	CcSEcCtD
Finasteride—Dizziness—Betamethasone—multiple sclerosis	0.000161	0.00236	CcSEcCtD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.00016	0.00208	CbGpPWpGaD
Finasteride—Dyspnoea—Methotrexate—multiple sclerosis	0.000158	0.00232	CcSEcCtD
Finasteride—Somnolence—Methotrexate—multiple sclerosis	0.000158	0.00231	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000157	0.00205	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.000157	0.00205	CbGpPWpGaD
Finasteride—Hypersensitivity—Prednisone—multiple sclerosis	0.000156	0.00229	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	0.000154	0.002	CbGpPWpGaD
Finasteride—Rash—Betamethasone—multiple sclerosis	0.000154	0.00225	CcSEcCtD
Finasteride—Rash—Dexamethasone—multiple sclerosis	0.000154	0.00225	CcSEcCtD
Finasteride—Dermatitis—Dexamethasone—multiple sclerosis	0.000154	0.00225	CcSEcCtD
Finasteride—Dermatitis—Betamethasone—multiple sclerosis	0.000154	0.00225	CcSEcCtD
Finasteride—Headache—Dexamethasone—multiple sclerosis	0.000153	0.00224	CcSEcCtD
Finasteride—Headache—Betamethasone—multiple sclerosis	0.000153	0.00224	CcSEcCtD
Finasteride—Asthenia—Prednisone—multiple sclerosis	0.000152	0.00223	CcSEcCtD
Finasteride—Pain—Methotrexate—multiple sclerosis	0.000152	0.00222	CcSEcCtD
Finasteride—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000152	0.00197	CbGpPWpGaD
Finasteride—Pruritus—Prednisone—multiple sclerosis	0.00015	0.0022	CcSEcCtD
Finasteride—SRD5A2—Metabolism—BCHE—multiple sclerosis	0.000149	0.00194	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—BCHE—multiple sclerosis	0.000149	0.00194	CbGpPWpGaD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000142	0.00185	CbGpPWpGaD
Finasteride—Urticaria—Methotrexate—multiple sclerosis	0.000141	0.00207	CcSEcCtD
Finasteride—Dizziness—Prednisone—multiple sclerosis	0.00014	0.00206	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	0.00014	0.00183	CbGpPWpGaD
Finasteride—Rash—Prednisone—multiple sclerosis	0.000134	0.00196	CcSEcCtD
Finasteride—Dermatitis—Prednisone—multiple sclerosis	0.000134	0.00196	CcSEcCtD
Finasteride—Headache—Prednisone—multiple sclerosis	0.000133	0.00195	CcSEcCtD
Finasteride—AKR1D1—Metabolism—BCHE—multiple sclerosis	0.000133	0.00173	CbGpPWpGaD
Finasteride—Hypersensitivity—Methotrexate—multiple sclerosis	0.000131	0.00192	CcSEcCtD
Finasteride—Asthenia—Methotrexate—multiple sclerosis	0.000127	0.00187	CcSEcCtD
Finasteride—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000127	0.00165	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000127	0.00165	CbGpPWpGaD
Finasteride—Pruritus—Methotrexate—multiple sclerosis	0.000126	0.00184	CcSEcCtD
Finasteride—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000125	0.00163	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000125	0.00163	CbGpPWpGaD
Finasteride—Dizziness—Methotrexate—multiple sclerosis	0.000117	0.00172	CcSEcCtD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000115	0.0015	CbGpPWpGaD
Finasteride—Rash—Methotrexate—multiple sclerosis	0.000112	0.00164	CcSEcCtD
Finasteride—Dermatitis—Methotrexate—multiple sclerosis	0.000112	0.00164	CcSEcCtD
Finasteride—Headache—Methotrexate—multiple sclerosis	0.000111	0.00163	CcSEcCtD
Finasteride—CYP3A7—Metabolism—SRM—multiple sclerosis	9.15e-05	0.00119	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—APOE—multiple sclerosis	8.95e-05	0.00116	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—APOE—multiple sclerosis	8.95e-05	0.00116	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—POMC—multiple sclerosis	8.48e-05	0.0011	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—APOE—multiple sclerosis	7.98e-05	0.00104	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—POMC—multiple sclerosis	7.69e-05	0.001	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—POMC—multiple sclerosis	7.69e-05	0.001	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—ALB—multiple sclerosis	7.01e-05	0.000912	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—ALB—multiple sclerosis	7.01e-05	0.000912	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—POMC—multiple sclerosis	6.85e-05	0.000892	CbGpPWpGaD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.62e-05	0.000861	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—SRM—multiple sclerosis	6.61e-05	0.000861	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	6.45e-05	0.000839	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	6.45e-05	0.000839	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—ALB—multiple sclerosis	6.25e-05	0.000813	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—POMC—multiple sclerosis	6.13e-05	0.000798	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—GPC5—multiple sclerosis	5.9e-05	0.000767	CbGpPWpGaD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	5.37e-05	0.000698	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—RRM1—multiple sclerosis	4.89e-05	0.000636	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	4.66e-05	0.000606	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	4.66e-05	0.000606	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—GPC5—multiple sclerosis	4.26e-05	0.000555	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—RRM1—multiple sclerosis	3.53e-05	0.00046	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—SRM—multiple sclerosis	3.08e-05	0.0004	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.85e-05	0.000371	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—BCHE—multiple sclerosis	2.81e-05	0.000365	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.17e-05	0.000282	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.17e-05	0.000282	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—BCHE—multiple sclerosis	2.03e-05	0.000264	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.98e-05	0.000258	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—APOE—multiple sclerosis	1.69e-05	0.00022	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.64e-05	0.000214	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—POMC—multiple sclerosis	1.45e-05	0.000189	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—ALB—multiple sclerosis	1.32e-05	0.000172	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—APOE—multiple sclerosis	1.22e-05	0.000159	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—POMC—multiple sclerosis	1.05e-05	0.000136	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—ALB—multiple sclerosis	9.56e-06	0.000124	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—BCHE—multiple sclerosis	9.43e-06	0.000123	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—APOE—multiple sclerosis	5.67e-06	7.38e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—POMC—multiple sclerosis	4.87e-06	6.34e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—ALB—multiple sclerosis	4.44e-06	5.78e-05	CbGpPWpGaD
